These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 34816388)
1. Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Conaghan P; Cohen S; Burmester G; Mysler E; Nash P; Tanaka Y; Rigby W; Patel J; Shaw T; Betts KA; Patel P; Liu J; Sun R; Fleischmann R Rheumatol Ther; 2022 Feb; 9(1):191-206. PubMed ID: 34816388 [TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM Rheumatol Ther; 2024 Jul; ():. PubMed ID: 39031276 [TBL] [Abstract][Full Text] [Related]
3. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230 [TBL] [Abstract][Full Text] [Related]
4. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Charles-Schoeman C; Giles JT; Lane NE; Choy E; Furst DE; Vencovský J; Wilson AG; Burmester GR; Coombs D; Penn SK; Khan N; Yee JB; Rahawi K; McInnes IB Rheumatol Ther; 2024 Feb; 11(1):157-175. PubMed ID: 38180720 [TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Winthrop KL; Nash P; Yamaoka K; Mysler E; Khan N; Camp HS; Song Y; Suboticki JL; Curtis JR Ann Rheum Dis; 2022 Feb; 81(2):206-213. PubMed ID: 34615638 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study. McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Haaland D; Chen L; Duan Y; Liu J; Lippe R; Wung P Rheumatol Ther; 2023 Feb; 10(1):275-292. PubMed ID: 36243812 [TBL] [Abstract][Full Text] [Related]
8. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rubbert-Roth A; Kakehasi AM; Takeuchi T; Schmalzing M; Palac H; Coombs D; Liu J; Anyanwu SI; Lippe R; Curtis JR Rheumatol Ther; 2024 Feb; 11(1):97-112. PubMed ID: 37982966 [TBL] [Abstract][Full Text] [Related]
9. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990 [TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. Fleischmann R; Mysler E; Bessette L; Peterfy CG; Durez P; Tanaka Y; Swierkot J; Khan N; Bu X; Li Y; Song IH RMD Open; 2022 Feb; 8(1):. PubMed ID: 35121639 [TBL] [Abstract][Full Text] [Related]
11. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Mysler E; Tanaka Y; Kavanaugh A; Aletaha D; Taylor PC; Song IH; Shaw T; Song Y; DeMasi R; Ali M; Fleischmann R Rheumatology (Oxford); 2023 May; 62(5):1804-1813. PubMed ID: 36018230 [TBL] [Abstract][Full Text] [Related]
12. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260 [TBL] [Abstract][Full Text] [Related]
13. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials. Conaghan PG; Pavelka K; Hsieh SC; Bonnington TL; Kent TC; Marchbank K; Edwards CJ Rheumatol Adv Pract; 2023; 7(1):rkad017. PubMed ID: 36794283 [TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993 [TBL] [Abstract][Full Text] [Related]
15. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Fleischmann R; Blanco R; Van den Bosch F; Bessette L; Song Y; Penn SK; McDearmon-Blondell E; Khan N; Chan K; Mysler E Rheumatol Ther; 2024 Jun; 11(3):599-615. PubMed ID: 38498140 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669 [TBL] [Abstract][Full Text] [Related]
18. Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). Burmester GR; Van den Bosch F; Tesser J; Shmagel A; Liu Y; Khan N; Camp HS; Kivitz A J Rheumatol; 2024 Jul; 51(7):663-672. PubMed ID: 38621793 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159 [TBL] [Abstract][Full Text] [Related]
20. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]